Ozempic maker Novo gets calls from ‘scared’ food CEOs for advice
Makers of everything from snack food to knee implants are facing a potential threat from Novo Nordisk’s powerful appetite-suppressing treatments. So they’re calling the drugmaker for advice.
By Naomi Kresge and Madison Muller, Bloomberg
“A couple of CEOs from, say, food companies have been calling me,” Novo’s Chief Executive Officer, Lars Fruergaard Jørgensen, said during a wide-ranging discussion in New York. He declined to name names, saying questions had centered on how the drugs work and how fast they would roll out. “They are scared about it.”
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
